S-3 filed Nov 16, 2026 at 17:11 ET
Acrivon Therapeutics filed a new S-3 shelf registration statement for up to $300 million in securities (common stock, preferred stock, debt securities, warrants, units), replacing a prior shelf with $292.7 million of unsold securities carried forward. The filing comes on the same day as Q3 2026 results showing $77.8 million in cash, expected to fund operations into Q4 2027, and no immediate pricing or offering was announced. The shelf provides broad financing flexibility for a clinical-stage biotech with no revenue and ongoing losses.